A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence
Interventions: DRUG: MM-121|DRUG: Irinotecan|DRUG: Cetuximab
Sponsor: Merrimack Pharmaceuticals
Collaborators: Sanofi